Serial No.: 09/830.548

Filed

: April 26, 2001

Page

REMARKS

Attornev's Doc

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted.

:: 06501-077001 / JI-A0004P-US

m

14

U

H

Reg. No. 34,819

Fish & Richardson P.C.

225 Franklin Street

Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20308486.doc

Page

: April 26, 2001

"Version With Markings to Show Changes Made"

In the specification:

Paragraph beginning at page 4, line 18, has been amended as follows:

The ligands for CD28 and CTLA-4 are CD80 (B7-1) and CD86 (B7-2) in human and mice. CTLA-4 has about 20 times as high affinity to both ligands as CD28. It has been elucidated that the amino acid sequence structures "MYPPPY (Met-Tyr-Pro-Pro-Pro-Tyr: SEO ID NO:1)" conserved through animal species is important for the binding of CD28 and CTLA-4 to CD80 (B7-1). It has also been reported that, when CD28 is stimulated, PI3 kinase (phosphoinositide 3 kinase, PI3K) associates with the phosphorylated tyrosine residue in a partial sequence "YMNM (Tyr-Met-Asn-Met: SEQ ID NO:2)" of CD28 and that CD28 plays an important role in intracellular signal transmission through this "YxxM" structure. Furthermore, it has been reported that CTLA-4 also has a sequence represented by "YxxM," namely "YVKM (Tyr-Val-Lys-Met: SEQ ID NO:3)" in its cytoplasmic region and that, after being stimulated, SYP associates with this sequence.